Research Projects & Grants

Federal

  • (MAS) Diabetic Retinopathy Clinical Research Network (DRCR), Role: Other Professional, Jaeb Center for Health Research, (03/2013 - 03/2025) Status: Awarded
  • Intravitreal ranibizumab or triamcinolone acetonide as adjunctive treatment to panretinal photocoagulation for proliferative diabetic retinopathy, Role: Investigator, National Eye Institute/NIH/DHHS, (01/2013 - 01/2014) Status: Completed
  • Age-related eye disease study 2 (AREDS 2): a multi-center, randomized trial of Lutein, zeaxanthin, and omega-3 long-chain polyunsaturated fatty acids (docosahexaenoic acid [DHA] and eicosapentaenoic acid [EPA] in age-related macular degeneration, Role: Investigator, National Eye Institute/NIH/DHHS, (12/2012 - 12/2013) Status: Completed
  • A pilot study in individuals with center-involved DME undergoing cataract surgery (Protocol P), Role: Investigator, National Eye Institute/NIH/DHHS, (08/2012 - 08/2013) Status: Completed
  • An observational study in individuals with diabetic retinopathy without center-involved DME undergoing cataract surgery (Protocol Q), Role: Investigator, National Eye Institute/NIH/DHHS, (08/2012 - 08/2013) Status: Completed
  • Subclinical diabetic macular edema, Role: Investigator, National Eye Institute/NIH/DHHS, (11/2009 - 11/2010) Status: Completed
  • A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema, Role: Investigator, National Eye Institute/NIH/DHHS, (05/2009 - 05/2010) Status: Completed
  • A phase 2 evaluation of anti-VEGF therapy for diabetic macular edema: bevacizumab (avastin), Role: Investigator, National Eye Institute/NIH/DHHS, (01/2009 - 01/2010) Status: Completed
  • The standard care versus corticosteroid for retinal vein occlusion (SCORE) study: Two randomized trials to compare the efficacy and safety of intravitreal injection(s) of triamcinolone acetonide with standard care to treat macular edema: One for central retinal vein occlusion and one for branch retinal vein occlusion, Role: Investigator, National Eye Institute/NIH/DHHS, (11/2008 - 11/2009) Status: Completed
  • A pilot study of peribulbar triamcinolone acetonide for diabetic macular edema, Role: Investigator, National Eye Institute/NIH/DHHS, (11/2007 - 11/2008) Status: Completed
  • An observational study of the development of diabetic macular edema following scatter laser photocoagulation, Role: Investigator, National Eye Institute/NIH/DHHS, (11/2007 - 11/2008) Status: Completed

For Profit Organization

  • Short-term evaluation of combination corticosteroid+anti-VEGF treatment for persistent central-involved diabetic macular edema following anti-VEGF therapy in pseudophakic eyes (protocol U), Role: Investigator, Diabetic Retinopathy Clinical Research Network (DRCRnet), (04/2017 - 04/2018) Status: Completed
  • A phase II, multicenter, randomized, single-masked, sham injection-controlled exposure-response study of lampalizumab intravitreal injections administered every two weeks or every four weeks to patients with geographic atrophy, Role: Investigator, Genentech, Inc., (10/2016 - 10/2017) Status: Completed
  • Home vision monitoring in AREDS2 for progression to neovascular AMD using the ForeseeHome device, Role: Investigator, Notal Vision, (07/2013 - 07/2014) Status: Completed
  • A Phase 2B Dose-Ranging Study of Pazopanib Eye Drops for the Treatment of Neovascular Age-Related Macular Degeneration (AMD), Role: Investigator, GlaxoSmithKline, (02/2012 - 02/2013) Status: Completed
  • A Randomized, Single-Masked, Long-Term, Safety, and Tolerability Study of Intravitreal VEGF Trap-Eye in Subjects with Neovascular Age-Related Macular Degeneration, Role: Investigator, Regeneron Pharmaceuticals, Inc., (07/2011 - 07/2012) Status: Completed
  • A randomized, double masked, active controlled phase III study of the efficacy, safety, and tolerability of repeated doses of intravitreal VEGF trap in subjects with neovascular age-related macular degeneration, Role: Investigator, Regeneron Pharmaceuticals, Inc., (04/2011 - 04/2012) Status: Completed
  • A multi-center, placebo-controlled, randomized, parallel-group dose-ranging study to assess the efficacy and safety of LX201 for prevention of corneal allograft rejection episodes and graft failure following penetrating keratoplasty with LX201 implantation in subjects who are at increased immunological risk, Role: Investigator, Lux Biosciences, Inc., (03/2010 - 03/2011) Status: Completed
  • A multi-center, placebo-controlled, randomized, parallel-group, dose-ranging study to assess the efficacy and safety of LX201 implantation for the prevention of corneal allograft rejection episodes or graft failure in subjects who have experienced one or more rejection episodes following penetrating keratoplasty, Role: Investigator, Lux Biosciences, Inc., (03/2010 - 03/2011) Status: Completed
  • FVF3426g: An open-label, multi-center extension study to evaluate the safety and tolerability of ranibizumab in subjects with choroidal neovascularization (CNV) secondary to age related macular degeneration (AMD) or macular edema secondary to retinal vein occlusion (RVO) who have completed a Genentech sponsored ranibizumab study, Role: Investigator, Genentech, Inc., (03/2010 - 03/2011) Status: Completed
  • A phase III, mulicenter, randomized, sham injection-controlled study of the efficacy and safety of ranizumab injection compared with sham in subjects with macular edema secondary to central retinal vein occlusion, Role: Investigator, Genentech, Inc., (05/2009 - 05/2010) Status: Completed
  • A phase III, mulicenter, randomized, sham injection-controlled study of the efficacy and safety of ranizumab injection compared with sham in subjects with macular edema secondary to branch retinal vein occlusion, Role: Investigator, Genentech, Inc., (05/2008 - 05/2009) Status: Completed
  • A pilot study of laser photocoagulation for diabetic macular edema, Role: Investigator, Diabetic Retinopathy Clinical Research Network (DRCRnet), (04/2008 - 04/2009) Status: Completed
  • An exploratory study of the safety, tolerability and biological effect of intravitreal administration of VEGF trap in patients with neovascular age-related macular degeneration [VGFT-OD-0502.00 04/07/2005; Investigator's Brochure Edition 1 04/05/05], Role: Investigator, Regeneron Pharmaceuticals, Inc., (04/2008 - 04/2009) Status: Completed
  • A six-month, phase 3, multicenter, masked, randomized, sham-controlled trial (with six-month open-label extension) to assess the safety and efficacy of 700 ug Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) applicator system in the treatment of patients with macular edema following central retinal vein occlusion or branch retinal vein occlusion, Role: Investigator, Allergan Inc., (03/2008 - 03/2009) Status: Completed
  • A randomized, controlled study of the safety, tolerability and biological effect of repeated intravitreal administration of VEGF trap in patients with neovascular age-related macular degeneration, Role: Investigator, Regeneron Pharmaceuticals, Inc., (04/2007 - 04/2008) Status: Completed
  • A phase III, multicenter, randomized, double-masked, sham injection-controlled study of the efficacy and safety of ranibizumab in subfoveal choroidal neovascularization (CNV) with or without classic CNV secondary to age-related macular degeneration [FVF3192g protocol date:6/4/2004], Role: Investigator, Genentech, Inc., (07/2006 - 07/2007) Status: Completed
  • MSI-1256F-209- A phase 2, multi-center, randomized, masked, controlled, study of MSI-1256F (Squalamine lactate) for the treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration, Role: Investigator, Genaera Corporation, (04/2006 - 03/2007) Status: Completed

Internal

  • A randomized, double-masked, parallel group, multicenter, dose-finding comparison of the safety and efficacy of ASI-001A 0.5 µg/day and ASI-0010B 0.2 µg/day fluocinolone acetonide intravitreal inserts to sham injection in subjects with diabetic macular edema, Role: Investigator, LLU Dept. of Ophthalmology, (08/2010 - 08/2011) Status: Completed

Non-Profit Organization

  • A phase III, double-masked, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection in subjects with clinically significant macular edema with center involvement secondary to diabetes mellitus, Role: Investigator, Genentech Foundation for Growth and Development, (04/2011 - 04/2012) Status: Completed